Molecular pharmacokinetic determinants of anticancer kinase inhibitors in humans

Phase I Clinical and Pharmacokinetic Study of the Novel Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor BAY 43-9006 in Patients With Advanced Refractory Solid Tumors

Dirk Strumberg, Heike Richly, Ralf A. Hilger et al. · Journal of Clinical Oncology · 2004 · 871 citations · Full text

Medicine, Oncology, Pharmacology +16

Active transport of imatinib into and out of cells: implications for drug resistance

Julia Thomas, Lihui Wang, Richard E. Clark et al. · Blood · 2004 · 640 citations · Full text

Life Sciences, Cell Biology, Pharmacology +14

OCT-1–mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib

Deborah L. White, Verity A Saunders, Phuong Dang et al. · Blood · 2006 · 432 citations · Full text

Life Sciences, Cell Biology, Pharmacology +6

Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump

Herman Burger, Hans van Tol, Antonius W.M. Boersma et al. · Blood · 2004 · 415 citations · Full text

Medicine, Molecular Biology, Oncology +11

Lapatinib (Tykerb, GW572016) Reverses Multidrug Resistance in Cancer Cells by Inhibiting the Activity of ATP-Binding Cassette Subfamily B Member 1 and G Member 2

Chun-ling Dai, Amit K. Tiwari, Chung‐Pu Wu et al. · Cancer Research · 2008 · 385 citations · Full text

Medicine, Oncology, Pharmacology +16